Table 2.

Univariate and multivariate analysis for survival of 147 HCC patients.

Clinical features	Univariate		Multivariate
	HR (95% CI)	P-value	HR (95% CI)	P-value
Overall survival:
Gender (female vs male)	0.938 (0.498–1.767)	0.843
Age (≥55 y vs <55 y)	1.068 (0.698–1.636)	0.761
HBV infection (negative vs positive)	0.717 (0.389–1.321)	0.286
Liver cirrhosis (absent vs present)	0.675 (0.425–1.072)	0.095
Child–Pugh (B vs A)	1.295 (0.761–2.205)	0.341
Tumor number (2–3 vs 1)	1.392 (0.784–2.470)	0.259
Tumor size (≥5 cm vs <5 cm)	2.501 (1.598–3.915)	<0.001	1.957 (1.224–3.135)	0.005
TNM stage (II–III vs I)	2.515 (1.634–3.871)	<0.001	1.786 (1.124–2.841)	0.014
Tumor differentiation (III–IV vs I–II)	1.017 (0.629–1.643)	0.946
AFP (≥400 vs <400)	0.763 (0.496–1.173)	0.218
HNRNPC (high vs low)	2.117 (1.349–3.322)	0.001	1.637 (1.025–2.611)	0.039
Disease-free survival:
Gender (female vs male)	0.876 (0.501–1.536)	0.645
Age (≥55 y vs <55 y)	1.090 (0.753–1.577)	0.649
HBV infection (negative vs positive)	0.736 (0.439–1.233)	0.244
Liver cirrhosis (absent vs present)	0.693 (0.466–1.028)	0.068
Child–Pugh (B vs A)	1.170 (0.728–1.881)	0.516
Tumor number (2–3 vs 1)	1.959 (1.184–3.241)	0.009	1.093 (0.620–1.927)	0.760
Tumor size (≥5 cm vs <5 cm)	1.830 (1.257–2.662)	0.002	1.348 (0.905–2.004)	0.142
TNM stage (II–III vs I)	2.572 (1.750–3.779)	<0.001	2.188 (1.471–3.257)	<0.001
Tumor differentiation (III–IV vs I–II)	1.099 (0.729–1.658)	0.652
AFP (≥400 vs <400)	1.387 (0.954–2.012)	0.086
HNRNPC (high vs low)	2.249 (1.525–3.317)	<0.001	1.883 (1.261–2.817)	0.002

HNRNPC, heterogeneous nuclear ribonucleoprotein C; HBV, hepatitis B virus; AFP, alpha fetoprotein.

The bold values present statistical significance.